Mutual of America Capital Management LLC Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Mutual of America Capital Management LLC purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 5,780 shares of the biopharmaceutical company’s stock, valued at approximately $321,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Natixis Advisors LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 290.0% in the third quarter. Natixis Advisors LLC now owns 52,562 shares of the biopharmaceutical company’s stock valued at $2,920,000 after purchasing an additional 39,086 shares in the last quarter. KBC Group NV increased its holdings in shares of Ultragenyx Pharmaceutical by 24.5% in the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 506 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 8.8% in the third quarter. Victory Capital Management Inc. now owns 10,948 shares of the biopharmaceutical company’s stock valued at $608,000 after purchasing an additional 884 shares in the last quarter. Atria Investments Inc acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $269,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $107,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 1.6 %

RARE opened at $48.13 on Friday. The stock has a market capitalization of $4.44 billion, a P/E ratio of -7.44 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37. The firm’s fifty day simple moving average is $52.48 and its 200 day simple moving average is $48.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm’s revenue was up 42.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.23) EPS. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. The trade was a 7.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,556 shares of company stock valued at $1,515,967. 5.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. HC Wainwright lifted their target price on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. lowered their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. Barclays lowered their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Finally, TD Cowen lifted their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.46.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.